Institute for Neurodegenerative Disorders
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Institute for Neurodegenerative Disorders sits in the top decile of US sponsors by registered trial count (#456 of 15,742 sponsors by registered trial count).
Institute for Neurodegenerative Disorders: 37 sponsored US clinical trials, none currently recruiting.
Institute for Neurodegenerative Disorders sponsors 37 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 26 completed. 1 of these trials are in Phase 3-4 (later-stage) and 33 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Parkinson Disease, with 4 trials.
Top-decile sponsor footprint
Institute for Neurodegenerative Disorders ranks in the top decile of sponsors by registered trial count (#456 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
26 of 37 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (70.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
37 total, page 1 of 1
Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS Patients
NCT01767493
Evaluation of [18F]MPPF as a Brain Tracer of Serotonin Receptor 5HT1a
NCT01461083
Research Involving Subjects With Parkinson's Disease, Alzheimer Disease and Healthy Controls
NCT01461109
Evaluation of [18F]MK-9470 as a Brain Tracer of Cannabinoid-1 Receptor in Parkinson's Disease and Healthy Subjects
NCT01462708
Evaluation of [18F] FMH3 and PET as a Marker of Histamine-3 Receptor Activity in Subjects With AD Compared w/ HC
NCT01268020
Safety and Efficacy of Positron Emission Tomography (PET) Imaging With MNI-558
NCT01217021
Evaluation of [18F] PBR111 and PET as a Marker of Inflammation in Subjects With Neurological Conditions
NCT01209156
Evaluation of [18F] PBR06 and PET as a Marker of Inflammation in Subjects With Neurological Conditions
NCT01028209
Safety and Efficacy of Positron Emission Tomography Imaging With MNI-513
NCT01000870
Evaluation of [18F] FEPPA and PET Imaging as a Marker of Inflammation in Subjects With Neurological Conditions
NCT00970333
Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in PD, HD and Healthy Subjects.
NCT00970229
A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions
NCT00870974
Single Photon Emission Computed Tomography (SPECT) Imaging Study to Develop a Biomarker for Alzheimer's Disease
NCT00886951
Brain Imaging Study in Subjects With Alzheimer Disease in Comparison to Healthy Subjects
NCT00870519
Evaluation of [123I] MNI-340 and SPECT as a Marker of Beta-Amyloid Protein Deposition
NCT00968097
Evaluation of [123I] MNI-330 and SPECT as a Marker of Beta-amyloid Protein Deposition
NCT00657813
Evaluation of [123I]CLINDE and SPECT as a Marker of Inflammation in Subjects With PD or AD and in Healthy Subjects
NCT00612872
Evaluation of [123I] AV51 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects
NCT00556660
Evaluation of [123I] AV94 and SPECT in Subjects With Alzheimer Disease in Comparison to Healthy Subjects
NCT00605059
Evaluation of [123I] AV151 and SPECT in Subjects w/ AD in Comparison to Healthy Subjects
NCT00605046
Development of Cognitive Assessment Tools in Parkinson Disease
NCT00556764
Assessment of the Effect of Sertaline on the Specific Binding of 123-I MZINT in Healthy Subjects
NCT00470925
Evaluation of [123I] MNI-187 and SPECT in Patients With Alzheimers Disease in Comparison to Healthy Subjects
NCT00456417
Evaluation of 123-I Iodobenzovesamicol (IBVM) and SPECT Imaging of Healthy Subjects and Patients With Alzheimer Disease
NCT00480701
Assessment of the Biodistribution and Safety of 123-I MZINT in Healthy Subjects and Parkinson Disease Patients
NCT00427674
Assessing Imaging as a Tool in Monitoring and Predicting the Progression of Parkinson Disease
NCT00404170
Evaluation of 5-[123I]-A-85380 and SPECT Imaging in Individuals With Parkinsons Disease
NCT00397696
The Study of the Impact of Disclosing Imaging Study Information to Trial Participants
NCT00354003
Biodistribution and Safety of a Radiopharmaceutical in Healthy Subjects
NCT00316797
Assess 123-I IMPY and SPECT Imaging as a Tool to Detect β-Amyloid in the Brain
NCT00287248
Imaging and Genetic Biomarkers of Parkinson Disease (PD) Onset and Progression in High-risk Families
NCT00273351
Development of Imaging, Clinical and Biochemical Bio-Markers for Parkinson's Disease
NCT00315250
A Study of the Sense of Smell in Relatives of Parkinson's Disease Patients
NCT00096876
Study of the Effects of Dopaminergic Medications on Dopamine Transporter Imaging in Parkinson's Disease
NCT00096720
A Study of Neurophysiologic Changes in Individuals With Parkinson's Disease
NCT00117195
Study of Individuals With Parkinson's Symptoms But in Whom There is Diagnostic Uncertainty
NCT00129675
A Study of Brain Imaging With Nuclear Medicine Technology in Individuals With and at Risk for Parkinson's Disease
NCT00117819
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 25 |
| Phase 2 | 8 |
| Phase 4 | 1 |
Therapeutic Areas
How the Institute for Neurodegenerative Disorders early-phase archive is shaped
37 indexed studies, none listed as recruiting (0% open); 26 completed (70%).
Phase mix: 1 late (III/IV) vs 33 early (I/II) (early-phase heavy).
Top condition: Parkinson Disease (4 trials), 3 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Institute for Neurodegenerative Disorders: archived-pipeline peers nationwide
Peers matched on 37 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Institute for Neurodegenerative Disorders sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 37 archived trials
- Appalachian State University · 37 trials · 3% recruiting
- Bracco Diagnostics · 37 trials · 3% recruiting
- Carnegie Mellon University · 37 trials · 11% recruiting
- Cutera · 37 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Institute for Neurodegenerative Disorders page
37 registered trials is a research-attention snapshot, not an endorsement of Institute for Neurodegenerative Disorders or any single study.
- None of Institute for Neurodegenerative Disorders's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Parkinson Disease is the condition Institute for Neurodegenerative Disorders studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Parkinson Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Institute for Neurodegenerative Disorders pipeline card: 37 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.